Bernstein SocGen on Nuvalent (NUVL): 'Extremely rare value creation by large cap pharma M&A'

June 10, 2026 9:11 AM

Bernstein SocGen Group analyst Jeffrey Walch reiterated an Outperform rating and $172.00 price target on Nuvalent (NASDAQ: NUVL).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found